Sensus Healthcare Inc. Common Stock (SRTS)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for businesses with durable earning power bought at a sensible price. Sensus sells a niche device, the SRT-100, that uses superficial radiation as an alternative to surgery for non-melanoma skin cancers. That is a real medical need, but a sixty-person device company faces reimbursement, adoption, and competition risks, and I see no wide moat in the figures. The numbers show a sharp reversal. In fiscal 2024, revenue was $41.8 million and net income was $6.6 million. In fiscal 2025, revenue fell to $27.5 million and net income became a loss of $7.7 million. The deterioration worsened in fiscal Q1 2026, the quarter ended 2026-03-31, with $3.4 million of revenue and a $2.6 million net loss, and in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $2.3 million with an $8.7 million net loss. Trailing free cash flow is negative $7.0 million, a FCF yield of negative 14.7%, and the FairStock P/E is negative 3.07 at the 2026-10-13 close. The balance sheet looks conservative with debt-to-equity of 0.01 and an Altman Z-Score of 7.07, and price-to-book is 1.29. But a Piotroski F-Score of 4/9 and ROE of negative 34.83% show weak current profitability. FairStock classifies it as a TURNAROUND, with a loss in the latest year after earlier profits. A Graham investor buying assets cheaply might glance at book value, but without stabilizing revenue and a return to positive cash flow, the cheapness is not margin of safety. I would need evidence of a real turn, not hope.

In plain English: Sensus Healthcare makes low-energy X-ray machines used to treat certain skin cancers. The business looks weak right now: revenue has dropped sharply and it is losing money. At $2.89, the price is not clearly cheap because there are no current profits to support it, though it is near its 52-week low and sells for a little above its accounting net worth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer